Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients
© Magnusson et al; licensee BioMed Central Ltd. 2010
Received: 23 October 2009
Accepted: 18 January 2010
Published: 18 January 2010
The aims of this study were to estimate the prevalence of left ventricular systolic (LVSD) and diastolic (LVDD) dysfunction, and to test if BNP and urinary albumin excretion rate (AER) are related to LVSD, LVD and left ventricular mass (LVM) in asymptomatic type 2 diabetes patients.
Presence of LVSD, LVDD and LVM, determined with echocardiography, was related to levels of BNP and AER in 153 consecutive asymptomatic patients with type 2 diabetes.
LVSD was present in 6.1% of patients whereas 49% (29% mild, 19% moderate and 0.7% severe) had LVDD and 9.4% had left ventricular hypertrophy. Increasing age (P < 0.0001) was the only independent variable related to mild LVDD whereas increasing BNP (P = 0.01), systolic blood pressure (P = 0.01), age (P = 0.003) and female gender (P = 0.04) were independent determinants of moderate to severe LVDD. AER (P = 0.003), age (P = 0.01) and male gender (P = 0.006) were directly and independently related to LVM.
About half of asymptomatic type 2 diabetes patients have LVDD. Of those, more than one third display moderate LVDD pattern paralleled by increases in BNP, suggesting markedly increased risk of heart failure, especially in females, whereas AER and male sex are related to LVM.
The steadily increasing prevalence of diabetes constitutes a major health problem. By the year 2025, the prevalence of diabetes is estimated to be as high as 5.4% . This is to be compared with reports from Swedish coronary care units, which suggest that as many as 66% of the patients admitted in fact have previously undiagnosed diabetes or pre-diabetes (impaired glucose tolerance) . Cardiovascular disease (CVD) is also the major contributor to mortality in the diabetic population . Screening for micro-vascular complications has been routine for decades, but no similar practice for early detection and treatment of cardiac complications has been conducted. This is especially notable, since treatment at different stages of heart dysfunction, even asymptomatic, has proved to reduce cardiovascular complications [4, 5]. It is also well known that microalbuminuria is a powerful predictor of CVD, especially in patients with type 2 diabetes , and this subset group would probably benefit even more from a cardiac screening. Routine echocardiography (echo) assessment would be considered optimal for such conduct, but is not always possible due to lack of accessibility. The measurement of the natriuretic peptides has been suggested as a tool to identify patients who could benefit from further risk evaluation by echo for the early detection and treatment of cardiac abnormalities . We have previously reported that, in a material of patients with type 2 diabetes without known cardiovascular disease, over 60% of the patients had N-terminal proBNP values above accepted cut off limits for the detection of cardiac abnormalities . However, no echo examinations were conducted in that study and it is unknown whether clinically easy-to-use markers like BNP and microalbuminuria can be used to identify type 2 diabetes patients with early signs of heart disease such as left ventricular dysfunction (LVD) and left ventricular hypertrophy (LVH). Therefore, in this study we set out to estimate the prevalence of left ventricular systolic dysfunction (LVSD), left ventricular diastolic dysfunction (LVDD) and LVH as measured by echo in a population of patients with type 2 diabetes and no history or symptoms of CVD, and further, in the same population, to test if BNP and urinary albumin excretion rate (AER) are related to LVSD, LVDD and left ventricular mass index (LVM) independently of each other, age, sex, diabetes duration, systolic blood pressure, metabolic control, lipid levels, body mass index and kidney function.
Materials and methods
Patients and protocol
Clinical characteristics of the study population.
Patients without LVDD n = 78 Mean
Patients with LVDD n = 75 Mean
50 ± 12
59 ± 10
Sex (% male)
134 ± 16
141 ± 16
79 ± 9.0
80 ± 8.0
73 ± 19
81 ± 42
137 ± 52
116 ± 41
lnAER ( g/min)
2.1 ± 1.3
2.3 ± 1.7
1.1 ± 1.0
1.6 ± 1.1
7.0 ± 2.0
6.5 ± 1.4
9.3 ± 3.8
8.9 ± 3.0
DM duration (years)
4,7 ± 6,6
8.0 ± 7.6
30 ± 6.1
31 ± 5.2
1.8 ± 1.1
1.8 ± 1.0
1.1 ± 0.3
1.2 ± 0.4
2.9 ± 0.8
2.7 ± 1.0
2.0 ± 0.24
2.0 ± 0.20
Patients without LVDD n = 78 Mean
Patients with LVDD n = 75 Mean
60 ± 6.2
56 ± 10
78 ± 15
79 ± 18
68 ± 15
97 ± 57
0.2 ± 0.06
0.2 ± 0.05
Pulmonary vein flow
1.4 ± 0.7
1.2 ± 0.6
RA diameter (mm/m2)
24 ± 4,5
25 ± 4.4
5.8 ± 1.0
6.0 ± 0.8
24 ± 2.5
24 ± 2.6
14 ± 1.9
15 ± 2.2
4.6 ± 0.7
4.5 ± 0.7
9.2 ± 6.8
7.7 ± 1.6
10 ± 6.7
6.7 ± 1.8
9.3 ± 2.0
10 ± 2.6
8.9 ± 2.4
8.4 ± 2.0
11 ± 3.2
9.1 ± 2.3
10 ± 3.6
11 ± 3.1
LA diameter (mm/m2)
20 ± 2.3
20 ± 1.9
87 ± 22
88 ± 25
Blood pressure was measured three times in the right arm in seated position after 10 min rest and the mean value of the three recordings was calculated. Korotkoff sounds corresponding to 'phase I' was used to define the systolic and 'phase V' the diastolic blood pressure. Hypertension was defined as systolic or diastolic blood pressure of 140/90 mmHg or greater or use of antihypertensive medication.
Diabetes mellitus was defined as a fasting whole blood glucose level greater than 109 mg/dL (6.0 mmol/L) or use of antidiabetic medication.
All patients underwent complete 2-dimensional echocardiography and Doppler studies in the left lateral decubitus position from multipline windows, using commercially available equipment (SONOS 7500, Philips Medical Systems, Andover, Massachusetts) with a phased array transducer of 2.5 MHz, and with a system equipped with Doppler tissue imaging technology. Pulsed Doppler tissue imaging is a new echo method based on the display of low frequency, high amplitude Doppler signals originated in the myocardium. A detailed concept and technical aspects of this approach have previously been published [9, 10]. All images were recorded during two cardiac cycles and were stored digitally and post processed.
In addition to pulsed Doppler tissue imaging, conventional echo was performed, including M-mode, 2-dimensional, pulsed and colour Doppler echocardiography. Right ventricular and left ventricular diameters, left and right atrium diameters, septal and posterior wall thickness were measured according to the recommendations of the American Society of Echocardiography, and left ventricular ejection fractions were calculated using the biplane Simpsons . The severity of valve regurgitations and stenoses was defined according to the clinical practice guidelines at Malmö University Hospital and in agreement with ACC/AHA guidelines .
The assessment of the severity of the valvular stenoses and regurgitations was performed using a combination of qualitative and quantitative analysis based on echocardiographic spectral and colour Doppler measurements.
PWTd: posterior wall thickness in diastole, SWTd: septal wall thickness in diastole, LVIDd: left ventricular inner diameter in diastole.
At the time of echocardiography, venous blood was sampled and transferred into pre-chilled EDTA vacutainers for analysis of BNP. Immediately after sampling the tubes were placed on ice and centrifuged at 4°C before plasma aliquots were frozen at -70°C for later analysis. Plasma BNP was measured with the Triage BNP Assay from Biosite Inc, San Diego, CA, using the UniCel™ immunoassay System from Beckman Coulter Inc, Brea, Ca. Lower limit of detection is 1 pg/mL (0.29 pmol/L). Within assay CVs are 3.1% and 1.0% at the levels of 40.8 and 1343 pg/mL. Corresponding between assay CVs are 4.5 and 6.6%. HbA1c was analysed using the Variant II chromatographic method from Bio-Rad (CA, USA) with a coefficient of variance (CV) of 3.0% at HbA1c 4.4-8.8%. The urinary albumin concentration was measured in over-night urine collections (12 hours) using an immunoturbimetric method (BeckmanCoulter, Beckman Instruments, CA, USA). Glomerular filtration rate (GFR) was calculated from the the Cockcroft-Gault formula; GFR (mL/min/1.73 m2) = ((140-age (years)) × body weight (kg))/(0.81 × Screat (mmol/l)) × (1:73 (m2)/BSA (m2))(×0.85 if female).
Normally distributed data are presented as means ± SD whereas data with skewed distributions are presented as medians and inter quartile ranges (IQR). Univariate differences in continuous variables was tested using Student's t-test with skewed variables being ln-transformed before analysis whereas chi-2 test was used to for differences in dichotomised variables. Correlation coefficients were calculated using Pearson's or Spearman's correlation analysis depending on normality of the residuals. Linear regressions, with skewed variables were ln transformed, and logistic regressions were used to test for multivariate relationships with continuous and dichotomous variables, respectively. All baseline variables (table 1) were entered into the multivariate models and were retained in the model if P < 0.05 using backward elimination. Two-sided tests were used and P < 0.05 was considered statistically significant throughout.
Clinical and biochemical characteristics are shown in table 1 and echo variables are shown in table 2. The mean blood pressure constitutes a mixture of blood pressure under treatment and untreated patients. On average patients had a LVM below the applied limits for LVH and 9.4% fulfilled the criteria for LVH. LVSD was only present in 6,1% of the subjects whereas 49% of the patients had echo signs of LVDD (29% mild, 19% moderate and 0.7% severe).
BNP and AER in relation to LVM
In a univariate analyses lnAER was significantly correlated (r = 0.34, P < 0.0001) and lnBNP showed a strong tendency without reaching the level of statistical significance (r = 0.17, P = 0.06) with LVM. However, in a multivariate linear regression model including all baseline covariates (table 1), only AER (unstandardized β coefficient (β) and (±SD) = 4.3 ± 1.4, P = 0.003), age (β = 0.48 ± 0.18, P = 0.01) and male gender (β = -13 ± 4.7, P = 0.006) remained independently related to LVM.
Correlations to diastolic dysfunction
When comparing patients with and without mild diastolic dysfunction (patients with moderate to severe LVDD excluded), we found no difference in lnBNP or lnAER, although there was a tendency towards higher lnBNP in patients with mild LVDD (1.3 ± 0.79 vs 0.98 ± 0.85, P = 0.09). Patients with mild LVDD were found to be significantly older (59 ± 7.6 vs 49 ± 11 years; P < 0.0001), have longer duration of diabetes (8.0 ± 8.0 vs. 4.6 ± 6.7 years; P = 0.02) and lower GFR (99 ± 27 vs 120 ± 33 ml/min/1.73 m2; P = 0.002). However, in a multivariate logistic regression analysis, increasing age (P < 0.0001) remained the only independent variable related to mild LVDD.
Although BNP is a well-established screening tool for LVSD and AER is routinely used for cardiovascular risk estimation, it is not known whether these two biomarkers are clinically useful for screening of LVDD and LVH in patients with type 2 diabetes with no prior CVD. The present study has demonstrated that echocardiographic screening of asymptomatic diabetic subjects without known CVD may identify significant numbers of patients with asymptomatic LVDD and LVH. We also show that BNP is independently related to moderate to severe LVDD whereas AER is directly and independently related to LVM.
Prevalence of subclinical heart disease in a diabetic population
Our data shows a prevalence of 49% of LVDD (29% mild, 19% moderate and 0.7% severe LVDD) in presumably heart healthy asymptomatic patients with type 2 diabetes. These findings are well in line with earlier studies i.e. data from Poirier et al were 46 men with type 2 diabetes who were aged 38-67 years; without evidence of diabetic complications, hypertension, coronary artery disease, congestive heart failure, or thyroid or overt renal disease; and with a maximal treadmill exercise test showing no ischemia, were studied. Twenty-eight of the subjects (60%) were found to have LVDD, of whom 13 (28%) had moderate LVDD and 15 (32%) had mild LVDD .
In our study, LVH was observed in only 9.4% of the patients. Fang et al. reported that in asymptomatic patients with diabetes mellitus without known cardiac disease, which underwent clinical evaluation and detailed echo assessment, approximately 20% fulfilled the criteria for LVH.
It has recently been published data by Srivastava and coworkers, showing a high prevalence of LVDD and LVH (59% and 70% respectively)  in patients with type 2 diabetes. As in our study, the prevalence of LVSD was fairly low (16%). The prevalence of LVH reported in that study is higher compared to our findings (70% v s 9.4%). However in that study population, 19% had known macrovascular disease. Interestingly, increasing age, diabetes duration and BMI were the only independent predictors of cardiac abnormalities. No differences regarding cardiac abnormalities between male and females were reported for .
BNP and correlations to echo abnormalities
We have previously reported that patients with type 2 diabetes have higher levels of BNP compared to patients without diabetes, indicating a high prevalence of asymptomatic heart disease . However, since no echo registrations were done in this study , no information regarding what underlying heart disease an elevated BNP value would represent could be obtained. For screening purposes BNP have been proven useful to rule out heart failure (HF) with impaired LVSD . BNP have also been shown useful for the assessment of LVDD at the population level  whereas its role for LVDD screening has not previously been investigated in type 2 diabetes patients with no prior CVD. We found that BNP is an independent determinant of moderate to severe LVDD. This is illustrated in figure 1 were BNP appears as good discriminator for the detection of moderate to severe LVDD in patients with type 2 diabetes. Henceforth, plasma BNP levels above 1.5 pmol/l indicates coexisting moderate diastolic dysfunction and further examination with echo would be warranted to further confirm this.
On the other hand, we did not found any significant relationship between BNP and mild LVDD or LVM, respectively. In accordance with the latter finding, screening with BNP for the presence of LVH in hypertensive patients has showed limited value .
AER and correlations to echocardiographical abnormalities
Whereas BNP was not associated to LVH, our data suggests that AER could be useful as a marker for LVH, as estimated by LVM, given its independent and direct relationship with LVM. An independent relationship between LVM and AER has not been reported earlier in type 2 diabetes and further emphasizes increased CVD risk and need of antihypertensive treatment in type 2 diabetes patients with microalbuminuria. Thus, this finding might serve as an explanatory model for the known risk of CVD in patients with microalbuminuria , since LVH is well associated with increased morbidity and mortality in CVD .
Male gender and left ventricular hypertrophy
The correlation between male gender and LVM is in line with the study by Concardy et al in 2004, in which it was shown that the LVH estimation without sex-specific criteria underestimated the prevalence of LVH in women and overestimates it in men, and even if sex specific definitions for LVH was used male gender still contributed to the prevalence of LVH in this study . Furthermore, an independent influence of increasing LVM and age were reported by Concardy et al and this influence was only seen in the male population of the study. Even if the patients studied by Concardy et al were hypertensive peers with higher prevalence of LVH (52.2%) compared to our diabetic population with a LVH prevalence of 9.4%, the data are in concordance with our findings and might represent a gender specific mechanism for the development of LVH. This is further supported by data from the Tromsö study in which male sex was found to be an independent predictor of LVH in a multivariate logistic regression analysis .
Female gender and diastolic dysfunction
Another interesting finding from the present study is the increased risk for moderate LVDD for female study subjects. The mechanism behind such a gender dependent pathophysiology is unclear. However, the results of the Framingham study revealed that between the ages of 45 and 75, men and women with diabetes had a two-fold- and five-fold increase in risk of developing heart failure, respectively, compared to patients without diabetes. This risk persisted even after considering age, blood pressure, cholesterol, weight, and history of coronary artery disease . Further studies are indeed warranted regarding this matter.
Screening for cardiac abnormalities in asymptomatic patients with type 2 diabetes
In our study almost half of the study population had LVDD and nearly ten percent had LVH. The treatment of LVH and LVSD is well established and has proved to reduce cardiovascular complication [4, 5]. However, the importance of diagnosing LVDD has just been acknowledged and the presence of LVDD provide essential prognostic information . Although the most effective treatment of LVDD in patients with type 2 diabetes is unknown, it is well established that an effective aggressive multifactorial approach indeed reduces micro- and macrovascular complications . Furthermore, recently published data suggests cardiovascular benefits of more aggressive blood pressure lowering therapy amongst patients with type 2 diabetes . Henceforth, an early detection of cardiac abnormalities such as LVSD, LVDD and LVH is crucial and might guide the clinicians to more intense risk factor management and aggressive pharmacological treatment of this high-risk population. Screening with echo would be considered optimal for such a conduct, but is not always eligible due to lack of accessibility and high cost. Our data suggest that the measurement of BNP and AER might be used as a screening tool in order to select patients for further work up with echo. However, the study sample size of a total of 153 subjects, which indeed is a respectable number for an echocardiographic study, might not be large enough to be definitive or inform clinical practice and therefore the results from the multivariate analysis needs to be confirmed in larger study samples.
In conclusion, this study has demonstrated that echo screening of asymptomatic diabetic subjects with apparently normal cardiac function may identify significant numbers of patients with asymptomatic LVDD and LVH. Almost half of the presumably heart healthy population had LVDD. BNP discriminates patients at high risk for moderate to severe LVDD, and might therefore be used as screening tool in order to capture patients eligible for further risk stratification with echo. LVH was associated with male gender and AER, whereas moderate LVDD was associated with female gender and BNP, implying gender specific mechanism in the development of CVD.
We thank Philippe Burri for excellent technical assistance. This study was supported by grants from Swedish Medical Research Council, the Swedish Heart and Lung Foundation, the Wallenberg Foundation, the Medical Faculty of Lund University, Malmö University Hospital, the Albert Påhlsson Research Foundation, the Crafoord foundation, the Ernhold Lundströms Research Foundation, the Region Skane, the Hulda and Conrad Mossfelt Foundation, the King Gustaf V and Queen Victoria Foundation and the Lennart Hanssons Memorial Fund.
- King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998, 21 (9): 1414-1431. 10.2337/diacare.21.9.1414.View ArticlePubMedGoogle Scholar
- Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002, 359 (9324): 2140-2144. 10.1016/S0140-6736(02)09089-X.View ArticlePubMedGoogle Scholar
- Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. Jama. 1999, 281 (14): 1291-1297. 10.1001/jama.281.14.1291.View ArticlePubMedGoogle Scholar
- Kostis JB: The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 1995, 8 (9): 909-914. 10.1016/0895-7061(95)00156-J.View ArticlePubMedGoogle Scholar
- Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002, 359 (9311): 1004-1010. 10.1016/S0140-6736(02)08090-X.View ArticlePubMedGoogle Scholar
- Gimeno-Orna JA, Molinero-Herguedas E, Sanchez-Vano R, Lou-Arnal LM, Boned-Juliani B, Castro-Alonso FJ: Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. Diabetes Res Clin Pract. 2006, 74 (1): 103-109. 10.1016/j.diabres.2006.03.008.View ArticlePubMedGoogle Scholar
- Struthers AD, Morris AD: Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002, 359 (9315): 1430-1432. 10.1016/S0140-6736(02)08358-7.View ArticlePubMedGoogle Scholar
- Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S: Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care. 2004, 27 (8): 1929-1935. 10.2337/diacare.27.8.1929.View ArticlePubMedGoogle Scholar
- Isaaz K, Thompson A, Ethevenot G, Cloez JL, Brembilla B, Pernot C: Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol. 1989, 64 (1): 66-75. 10.1016/0002-9149(89)90655-3.View ArticlePubMedGoogle Scholar
- Miyatake K, Yamagishi M, Tanaka N, Uematsu M, Yamazaki N, Mine Y, Sano A, Hirama M: New method for evaluating left ventricular wall motion by color-coded tissue Doppler imaging: in vitro and in vivo studies. J Am Coll Cardiol. 1995, 25 (3): 717-724. 10.1016/0735-1097(94)00421-L.View ArticlePubMedGoogle Scholar
- Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, et al: Recommendations for chamber quantification. Eur J Echocardiogr. 2006, 7 (2): 79-108. 10.1016/j.euje.2005.12.014.View ArticlePubMedGoogle Scholar
- Bonow RO, Carabello BA, Kanu C, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, et al: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006, 114 (5): e84-231. 10.1161/CIRCULATIONAHA.106.176857.View ArticlePubMedGoogle Scholar
- Paulus Walter J, Tschope C, Sanderson John E, Rusconi C, Flachskampf Frank A, Rademakers Frank E, Marino P, Smiseth Otto A, De Keulenaer G, Leite-Moreira Adelino F, et al: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European heart journal. 2007, 28 (20): 2539-10.1093/eurheartj/ehm037.View ArticlePubMedGoogle Scholar
- Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001, 24 (1): 5-10. 10.2337/diacare.24.1.5.View ArticlePubMedGoogle Scholar
- Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burrell LM: Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. Clin Sci (Lond). 2008, 114 (4): 313-320. 10.1042/CS20070261.View ArticleGoogle Scholar
- Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J: Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 2001, 310 (2): 193-197. 10.1016/S0009-8981(01)00578-2.View ArticlePubMedGoogle Scholar
- Lukowicz TV, Fischer M, Hense HW, Doring A, Stritzke J, Riegger G, Schunkert H, Luchner A: BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy. Eur J Heart Fail. 2005, 7 (4): 525-531. 10.1016/j.ejheart.2004.12.010.View ArticlePubMedGoogle Scholar
- Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K: The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens. 2003, 16 (12): 1025-1029. 10.1016/j.amjhyper.2003.07.024.View ArticlePubMedGoogle Scholar
- Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001, 141 (3): 334-341. 10.1067/mhj.2001.113218.View ArticlePubMedGoogle Scholar
- Conrady AO, Zaharov DV, Krutikov AN, Vahrameeva NV, Yakovleva OI, Alexeeva NP, Shlyakhto EV, Rudomanov OG: Prevalence and determinants of left ventricular hypertrophy and remodelling patterns in hypertensive patients: the St. Petersburg study. Blood Pressure. 2004, 13 (2): 101-10.1080/08037050410031855.View ArticlePubMedGoogle Scholar
- Schirmer H, Lunde P, Rasmussen K: Prevalence of left ventricular hypertrophy in a general population; The Tromso Study. Eur Heart J. 1999, 20 (6): 429-438. 10.1053/euhj.1998.1314.View ArticlePubMedGoogle Scholar
- Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. Jama. 1979, 241 (19): 2035-2038. 10.1001/jama.241.19.2035.View ArticlePubMedGoogle Scholar
- Sanderson JE, Wang M, Yu CM: Tissue Doppler imaging for predicting outcome in patients with cardiovascular disease. Curr Opin Cardiol. 2004, 19 (5): 458-463. 10.1097/01.hco.0000133110.58863.52.View ArticlePubMedGoogle Scholar
- Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008, 358 (6): 580-591. 10.1056/NEJMoa0706245.View ArticlePubMedGoogle Scholar
- Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007, 370 (9590): 829-840. 10.1016/S0140-6736(07)61303-8.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.